Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA
25/03/2026 15:26
March 25 (Reuters) - Lee's Pharmaceutical 0950.HK: APPROVAL OF INTRAROSA BY NMPA ON 17 MARCH NMPA GRANTED APPROVAL FOR COSETTE PHARMACEUTICALS' INTRAROSA Further company coverage: 0950.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals